Free Trial
NASDAQ:ASMB

Assembly Biosciences Q2 2025 Earnings Report

Assembly Biosciences logo
$21.22 +1.79 (+9.21%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$22.35 +1.13 (+5.33%)
As of 08:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Assembly Biosciences EPS Results

Actual EPS
-$1.33
Consensus EPS
-$1.73
Beat/Miss
Beat by +$0.40
One Year Ago EPS
N/A

Assembly Biosciences Revenue Results

Actual Revenue
$9.63 million
Expected Revenue
$5.30 million
Beat/Miss
Beat by +$4.33 million
YoY Revenue Growth
N/A

Assembly Biosciences Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 6, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Assembly Biosciences' Q3 2025 earnings is scheduled for Thursday, August 14, 2025

Assembly Biosciences Earnings Headlines

GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live.
Assembly Biosciences (ASMB) Expected to Announce Earnings on Thursday
See More Assembly Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Assembly Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Assembly Biosciences and other key companies, straight to your email.

About Assembly Biosciences

Assembly Biosciences (NASDAQ:ASMB), a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

View Assembly Biosciences Profile

More Earnings Resources from MarketBeat